VRTX · Healthcare
Vertex Pharmaceuticals Inc
42/100
Smart-money confidence1 of 3 sources positive
Below average interest
No standout activity across the feeds we track.
What this band has actually done: stocks scoring 25–45 beat the S&P 500 over the next three months 45.3% of the time, across 39,662 cases since 2015. That is below a coin flip — and so is every other band, because the median stock loses to a cap-weighted index. How we measured this
Hedge funds
55
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$133.3B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGS
About VERTEX PHARMACEUTICALS INC
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of…
Who's behind the signal
Every informed buyer we can see on VRTX, across all three feeds.
Hedge funds · 11
Tudor Investment (Paul Tudor Jones)
New position
Point72 (Steve Cohen)
New position
Millennium Management (Englander)
Increased +1420%
Citadel Advisors
Increased +50%
Baillie Gifford & Co
Increased +37%
AQR Capital Management
Increased +260%
+5 more in the full breakdown below ↓
Congress · 14
David J. Taylor
sold
Alan Armstrong
bought
Lisa C. McClain
sold
Jefferson Shreve
sold
Byron Donalds
sold
Julia Letlow
bought
Tommy Tuberville
sold
Greg Stanton
sold
+6 more in the full record below ↓
Insiders
No significant Form 4 insider activity in the window.
Congressional trades · 23 on record
Disclosures from 2015-05-13 to 2026-08-26
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2026-08-26 | David J. Taylor · R-OH | House | Sold | $1,001 - $15,000 |
| 2026-03-27 | Alan Armstrong · R-OK | Senate | Bought | $1,001 - $15,000 |
| 2026-01-29 | David J. Taylor · R-OH | House | Sold | $1,001 - $15,000 |
| 2025-08-07 | David J. Taylor · R-OH | House | Bought | $1,001 - $15,000 |
| 2025-06-11 | Lisa C. McClain · R-MI | House | Sold | $1,001 - $15,000 |
| 2025-06-10 | Lisa C. McClain · R-MI | House | Sold | $1,001 - $15,000 |
| 2025-05-12 | Jefferson Shreve · R-IN | House | Sold | $15,001 - $50,000 |
| 2025-03-20 | Byron Donalds · R-FL | House | Sold | $1,001 - $15,000 |
| 2025-03-13 | Jefferson Shreve · R-IN | House | Bought | $15,001 - $50,000 |
| 2025-02-24 | Jefferson Shreve · R-IN | House | Bought | $15,001 - $50,000 |
Show the other 13
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2024-12-11 | Lisa C. McClain · R-MI | House | Bought | $1,001 - $15,000 |
| 2024-10-23 | Julia Letlow · R-LA | House | Bought | $1,001 - $15,000 |
| 2024-05-03 | Tommy Tuberville · R-AL | Senate | Sold | $1,001 - $15,000 |
| 2023-10-24 | Greg Stanton · D-AZ | House | Sold | $1,001 - $15,000 |
| 2022-03-29 | William R. Keating · D-MA | House | Bought | $1,001 - $15,000 |
| 2021-01-28 | Peter Meijer · R-MI | House | Sold | $1,001 - $15,000 |
| 2020-12-18 | Dean Phillips · D-MN | House | Bought | $1,001 - $15,000 |
| 2020-11-19 | Kenny Marchant · R-TX | House | Sold | $1,001 - $15,000 |
| 2019-06-24 | Donna E. Shalala · D-FL | House | Sold | $1,001 - $15,000 |
| 2019-04-18 | Donna E. Shalala · D-FL | House | Bought | $1,001 - $15,000 |
| 2019-02-04 | Jack Reed · D-RI | Senate | Sold | $1,001 - $15,000 |
| 2018-03-09 | Jack Reed · D-RI | Senate | Sold | $1,001 - $15,000 |
| 2015-05-13 | Jack Reed · D-RI | Senate | Sold | $1,001 - $15,000 |
Not a model pick — but on our radar.
VERTEX PHARMACEUTICALS INC isn't in the top-10 model right now, but 11 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
11
Investors
2
New positions
4
Increasing
4
Decreasing
1
Unchanged
Price History
Loading price data...
A member of Congress bought
A member sold
Return:
High:
Low:
Markers sit on the transaction date the member disclosed, snapped to the nearest close on the chart. They are not the date the public found out — that came later, and the gap is its own page. Every marker is listed by name in the table above.
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.2×
% of portfolio
0.1%
Position change
NEW
0.1% of Tudor Investment's portfolio
Trust weight: 1.1×
% of portfolio
0.0%
Position change
NEW
0.0% of Point72's portfolio
Trust weight: 1.0×
% of portfolio
0.2%
Position change
+1420%
0.2% of Millennium Management's portfolio
Trust weight: 1.0×
% of portfolio
0.1%
Position change
+50%
0.1% of Citadel Advisors's portfolio
Trust weight: 1.4×
% of portfolio
0.1%
Position change
+37%
0.1% of Baillie Gifford & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.1%
Position change
+260%
0.1% of AQR Capital Management's portfolio
Trust weight: 1.2×
% of portfolio
1.5%
Position change
—
1.5% of Tweedy Browne's portfolio
Trust weight: 1.0×
% of portfolio
0.2%
Position change
−24%
0.2% of Renaissance Technologies's portfolio
Trust weight: 1.1×
% of portfolio
0.0%
Position change
−9%
0.0% of Gotham Asset Mgmt's portfolio
Trust weight: 1.3×
% of portfolio
0.0%
Position change
−19%
0.0% of Bridgewater Associates's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−99%
0.0% of D.E. Shaw & Co's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to VERTEX PHARMACEUTICALS INC
Insider Trading (Form 4)
Recent trades by company officers and directors — filed within 2 days of each trade
Neutral
Sentiment
0
Buys
3
Sells
| Date | Insider | Title | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-02 | McKechnie Duncan | Insider | SELL | 1,541 | $519.00 | $799,779 |
| 2026-07-02 | Tatsis Ourania | Insider | SELL | 1,500 | $524.99 | $787,485 |
| 2026-07-01 | Liu Joy | Insider | SELL | 828 | $502.71 | $416,244 |
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell VERTEX PHARMACEUTICALS INC or any security.
Get the Weekly Update
Every week, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime